Literature DB >> 25911129

Malignancy of bladder cancer cells is enhanced by tumor-associated fibroblasts through a multifaceted cytokine-chemokine loop.

Susanne Grimm1, Susanne Jennek1, Rajan Singh1, Astrid Enkelmann2, Kerstin Junker2, Nora Rippaus1, Alexander Berndt3, Karlheinz Friedrich4.   

Abstract

The microenvironment of tumor cells is critically involved in tumor development and progression. Tumor-associated fibroblasts (TAFs) represent a major constituent of the tumor stroma. Tumor cells are operative in the activation of TAFs, whereas TAFs in turn contribute to tumor cell malignancy. This report describes mechanisms of communication between fibroblasts and urinary bladder cancer (UBC) cells. Migration of bladder cancer cell lines RT112 and Cal-29, representing two different grades of dedifferentiation, was enhanced by cocultivation with TAFs. Conditioned medium from tumor cells induced the release of interleukin (IL)-8, hepatocyte growth factor (HGF), matrix metalloproteinase-2, granulocyte macrophage colony-stimulating factor, and monocyte chemotactic protein (MCP)-1 by TAFs. Tumor cell-derived IL-1α was identified as a major mediator of these stimulatory effects. Fibroblasts, on the other hand, exerted a migration and invasion stimulating influence on UBC cells. MCP-1 and HGF were shown to promote cell migration of both bladder cancer cell lines.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Interleukin-8; Matrix metalloproteinases; Microenvironment; Tumor stroma; Tumor-associated fibroblasts

Mesh:

Substances:

Year:  2015        PMID: 25911129     DOI: 10.1016/j.yexcr.2015.04.001

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  13 in total

Review 1.  [Tumour-stroma interactions in urothelial cancer].

Authors:  J Hatina; M Kripnerová; J Tuková; J Šrámek; P Dvořák; M Pešta; J Dobrá; V Babuška; J Racek; M Sobol; A Philimonenko; P Hozák; Z Czuba; W A Schulz; C Strell; S Grimm; S Jennek; K-H Friedrich
Journal:  Urologe A       Date:  2015-04       Impact factor: 0.639

2.  Endothelial cell tumor growth is Ape/ref-1 dependent.

Authors:  Ayan Biswas; Savita Khanna; Sashwati Roy; Xueliang Pan; Chandan K Sen; Gayle M Gordillo
Journal:  Am J Physiol Cell Physiol       Date:  2015-06-24       Impact factor: 4.249

Review 3.  c-Met expression and activity in urogenital cancers - novel aspects of signal transduction and medical implications.

Authors:  Ralf Hass; Susanne Jennek; Yuanyuan Yang; Karlheinz Friedrich
Journal:  Cell Commun Signal       Date:  2017-02-17       Impact factor: 5.712

Review 4.  Stromal Androgen Receptor in Prostate Cancer Development and Progression.

Authors:  Damien A Leach; Grant Buchanan
Journal:  Cancers (Basel)       Date:  2017-01-22       Impact factor: 6.639

Review 5.  Epigenetics of Bladder Cancer: Where Biomarkers and Therapeutic Targets Meet.

Authors:  Victor G Martinez; Ester Munera-Maravilla; Alejandra Bernardini; Carolina Rubio; Cristian Suarez-Cabrera; Cristina Segovia; Iris Lodewijk; Marta Dueñas; Mónica Martínez-Fernández; Jesus Maria Paramio
Journal:  Front Genet       Date:  2019-11-18       Impact factor: 4.599

6.  Fibroblasts in urothelial bladder cancer define stroma phenotypes that are associated with clinical outcome.

Authors:  Artur Mezheyeuski; Ulrika Segersten; Lina Wik Leiss; Per-Uno Malmström; Jiri Hatina; Arne Östman; Carina Strell
Journal:  Sci Rep       Date:  2020-01-14       Impact factor: 4.379

Review 7.  CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of the Ligands of Receptors CCR1, CCR2, CCR3, and CCR4.

Authors:  Jan Korbecki; Klaudyna Kojder; Donata Simińska; Romuald Bohatyrewicz; Izabela Gutowska; Dariusz Chlubek; Irena Baranowska-Bosiacka
Journal:  Int J Mol Sci       Date:  2020-11-09       Impact factor: 5.923

Review 8.  Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer.

Authors:  Jelmer H van Puffelen; Samuel T Keating; Egbert Oosterwijk; Antoine G van der Heijden; Mihai G Netea; Leo A B Joosten; Sita H Vermeulen
Journal:  Nat Rev Urol       Date:  2020-07-16       Impact factor: 14.432

Review 9.  Immunomodulatory aspects in the progression and treatment of oral malignancy.

Authors:  Nobuo Kondoh; Masako Mizuno-Kamiya; Naoki Umemura; Eiji Takayama; Harumi Kawaki; Kenji Mitsudo; Yasunori Muramatsu; Shinichiro Sumitomo
Journal:  Jpn Dent Sci Rev       Date:  2019-10-07

Review 10.  The interplay of extracellular matrix and microbiome in urothelial bladder cancer.

Authors:  Massimo Alfano; Filippo Canducci; Manuela Nebuloni; Massimo Clementi; Francesco Montorsi; Andrea Salonia
Journal:  Nat Rev Urol       Date:  2015-12-15       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.